Roche Holding AG (RHHVF)
261.49
+0.23
(+0.09%)
USD |
OTCM |
May 17, 16:00
Roche Enterprise Value: 235.43B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 235.43B |
| May 16, 2024 | 235.25B |
| May 15, 2024 | 224.87B |
| May 14, 2024 | 221.60B |
| May 13, 2024 | 220.36B |
| May 10, 2024 | 222.53B |
| May 09, 2024 | 221.57B |
| May 08, 2024 | 219.39B |
| May 07, 2024 | 221.49B |
| May 06, 2024 | 212.94B |
| May 03, 2024 | 216.14B |
| May 02, 2024 | 214.55B |
| May 01, 2024 | 215.11B |
| April 30, 2024 | 217.34B |
| April 29, 2024 | 218.40B |
| April 26, 2024 | 220.18B |
| April 25, 2024 | 216.48B |
| April 24, 2024 | 219.50B |
| April 23, 2024 | 226.91B |
| April 22, 2024 | 222.43B |
| April 19, 2024 | 221.47B |
| April 18, 2024 | 218.35B |
| April 17, 2024 | 220.39B |
| April 16, 2024 | 221.09B |
| April 15, 2024 | 221.87B |
| Date | Value |
|---|---|
| April 12, 2024 | 222.22B |
| April 11, 2024 | 224.12B |
| April 10, 2024 | 222.77B |
| April 09, 2024 | 221.97B |
| April 08, 2024 | 220.11B |
| April 05, 2024 | 220.32B |
| April 04, 2024 | 223.56B |
| April 03, 2024 | 226.47B |
| April 02, 2024 | 226.28B |
| April 01, 2024 | 228.19B |
| March 28, 2024 | 231.18B |
| March 27, 2024 | 228.19B |
| March 26, 2024 | 226.43B |
| March 25, 2024 | 228.63B |
| March 22, 2024 | 226.93B |
| March 21, 2024 | 227.31B |
| March 20, 2024 | 234.26B |
| March 19, 2024 | 233.49B |
| March 18, 2024 | 232.37B |
| March 15, 2024 | 236.14B |
| March 14, 2024 | 237.59B |
| March 13, 2024 | 244.05B |
| March 12, 2024 | 249.70B |
| March 11, 2024 | 244.45B |
| March 08, 2024 | 243.15B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
212.94B
Minimum
May 06 2024
368.05B
Maximum
Dec 29 2021
286.62B
Average
285.91B
Median
Mar 19 2021
Enterprise Value Benchmarks
| AC Immune SA | 198.33M |
| CRISPR Therapeutics AG | 2.666B |
| Addex Therapeutics Ltd | 4.792M |
| NLS Pharmaceutics Ltd | 7.841M |
| Molecular Partners AG | -98.31M |
Enterprise Value Related Metrics
| Earnings Yield | 6.12% |
| Operating Earnings Yield | 8.19% |
| Normalized Earnings Yield | 6.194 |